Abaxis (ABAX) Earning Negative News Coverage, AlphaOne Reports

Abaxis (ABAX) Earning Negative News Coverage, AlphaOne Reports

These are some of the media headlines that may have impacted Alpha One Sentiment Analysis’s rankings:

News articles about Abaxis (NASDAQ:ABAX) have been trending negative on Wednesday, AlphaOne Sentiment reports. The research group, a division of Accern, ranks the sentiment of press coverage by analyzing more than twenty million blog and news sources in real-time. AlphaOne ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Abaxis earned a coverage optimism score of -0.35 on AlphaOne’s scale. AlphaOne also assigned news coverage about the medical research company an impact score of 66 out of 100, meaning that recent press coverage is likely to have an impact on the stock’s share price in the immediate future.

Several equities analysts have commented on the stock. Zacks Investment Research downgraded shares of Abaxis from a “hold” rating to a “sell” rating in a report on Monday, May 1st. Canaccord Genuity reiterated a “hold” rating and issued a $48.00 price objective on shares of Abaxis in a report on Tuesday, February 14th. Finally, Seaport Global Securities upgraded shares of Abaxis to a “buy” rating in a report on Wednesday, February 1st. Three investment analysts have rated the stock with a sell rating, three have issued a hold rating and two have assigned a buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus price target of $45.00.

Abaxis (NASDAQ:ABAX) opened at 49.75 on Wednesday. The firm has a 50 day moving average of $47.92 and a 200 day moving average of $49.82. The firm has a market capitalization of $1.12 billion, a P/E ratio of 34.62 and a beta of 0.88. Abaxis has a 12-month low of $43.57 and a 12-month high of $55.95.

Abaxis (NASDAQ:ABAX) last released its earnings results on Thursday, April 27th. The medical research company reported $0.33 EPS for the quarter, hitting the Zacks’ consensus estimate of $0.33. The company had revenue of $58.20 million for the quarter, compared to analysts’ expectations of $58.04 million. Abaxis had a return on equity of 12.02% and a net margin of 15.06%. The business’s revenue for the quarter was up 2.2% compared to the same quarter last year. During the same period in the previous year, the business posted $0.36 EPS. On average, analysts forecast that Abaxis will post $1.22 EPS for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Thursday, June 15th. Stockholders of record on Thursday, June 1st will be paid a dividend of $0.14 per share. This represents a $0.56 dividend on an annualized basis and a dividend yield of 1.13%. The ex-dividend date of this dividend is Tuesday, May 30th. Abaxis’s payout ratio is 37.58%.

In other news, Director Achim Henkel sold 8,650 shares of Abaxis stock in a transaction on Monday, May 8th. The stock was sold at an average price of $47.75, for a total transaction of $413,037.50. Following the sale, the director now directly owns 68,150 shares in the company, valued at approximately $3,254,162.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 4.10% of the company’s stock.

Abaxis Company Profile

Abaxis, Inc is a developer, manufacturer and marketer of portable blood analysis systems that are used in medical specialties in human or veterinary patient care to provide clinicians with blood constituent measurements. The Company markets and sells its products around the world through independent distributors and direct sales force.new TradingView.widget({ “height”: 400, “width”: 625, “symbol”: “NASDAQ:ABAX”, “interval”: “D”, “timezone”: “Etc/UTC”, “theme”: “White”, “style”: “1”, “locale”: “en”, “toolbar_bg”: “#f1f3f6”, “enable_publishing”: false, “hideideas”: true, “referral_id”: “2588”});

Related posts

Leave a Comment